Table 2. Laboratory findings and treatment of patients on admission

|  | | | **Mortality** | |  |
| --- | --- | --- | --- | --- | --- |
| **Group** | **Characteristic** | **All patients** (n = 287)1 | **Survivor** (n = 155)1 | **Non-survivor** (n = 132)1 | **p value**2 |
| Laboratory findings | White-cells (×10−9/L) | 10.6 (7.8, 16.6) | 9.0 (6.5, 13.1) | 14.5 (10.0, 19.2) | **<0.001** |
|  | White-cells (×10−9/L) |  |  |  | **<0.001** |
|  | 4-10 | 104 (38.7%) | 75 (50.3%) | 29 (24.2%) |  |
|  | < 4 | 19 (7.1%) | 15 (10.1%) | 4 (3.3%) |  |
|  | 10 | 146 (54.3%) | 59 (39.6%) | 87 (72.5%) |  |
|  | Neutrophils (×10−9/L) | 9.0 (6.0, 14.8) | 7.2 (4.5, 11.7) | 13.0 (8.8, 17.9) | **<0.001** |
|  | Neutrophils (×10−9/L) |  |  |  | **<0.001** |
|  | <= 6.3 | 91 (31.7%) | 67 (43.2%) | 24 (18.2%) |  |
|  | 6.3 | 196 (68.3%) | 88 (56.8%) | 108 (81.8%) |  |
|  | Lymphocytes (×10−9/L) | 0.9 (0.6, 1.3) | 1.0 (0.7, 1.5) | 0.7 (0.4, 1.2) | **<0.001** |
|  | Lymphocytes (×10−9/L) |  |  |  | **0.010** |
|  | = 1 | 141 (49.1%) | 87 (56.1%) | 54 (40.9%) |  |
|  | < 1 | 146 (50.9%) | 68 (43.9%) | 78 (59.1%) |  |
|  | Platelets (×10−9/L) | 254.5 (193.5, 342.0) | 255.0 (190.0, 344.0) | 251.0 (200.0, 331.0) | 0.93 |
|  | Platelets (×10−9/L) |  |  |  | 0.88 |
|  | = 125 | 266 (92.7%) | 144 (92.9%) | 122 (92.4%) |  |
|  | < 125 | 21 (7.3%) | 11 (7.1%) | 10 (7.6%) |  |
|  | MCV (mm3) | 90.9 (87.7, 93.6) | 90.2 (87.2, 92.8) | 91.3 (88.2, 94.4) | **0.048** |
|  | MCH (pg) | 29.3 (28.1, 30.3) | 29.2 (27.9, 30.1) | 29.4 (28.4, 30.6) | **0.045** |
|  | Hemoglobin (g/dL) | 13.7 (12.0, 14.9) | 13.7 (12.6, 15.0) | 13.7 (11.4, 14.9) | 0.42 |
|  | Hemoglobin (g/dL) |  |  |  | **0.022** |
|  | 12 | 216 (75.3%) | 125 (80.6%) | 91 (68.9%) |  |
|  | <= 12 | 71 (24.7%) | 30 (19.4%) | 41 (31.1%) |  |
|  | Hematocrit (%) | 42.0 (37.5, 46.0) | 42.7 (38.5, 46.0) | 41.7 (35.3, 46.0) | 0.23 |
|  | Hematocrit (%) |  |  |  | **0.031** |
|  | = 36 | 229 (79.8%) | 131 (84.5%) | 98 (74.2%) |  |
|  | < 36 | 58 (20.2%) | 24 (15.5%) | 34 (25.8%) |  |
|  | Serum creatinine (mg/dL) | 0.8 (0.6, 1.2) | 0.7 (0.6, 1.0) | 1.0 (0.7, 1.5) | **<0.001** |
|  | Serum creatinine (mg/dL) |  |  |  | **0.001** |
|  | < 1.3 | 213 (74.2%) | 127 (81.9%) | 86 (65.2%) |  |
|  | = 1.3 | 74 (25.8%) | 28 (18.1%) | 46 (34.8%) |  |
|  | BUN (mg/dL) | 36.1 (26.8, 52.0) | 32.0 (24.0, 44.0) | 42.5 (30.0, 56.5) | **<0.001** |
|  | BUN (mg/dL) |  |  |  | **0.025** |
|  | < 20 | 30 (10.5%) | 22 (14.2%) | 8 (6.1%) |  |
|  | = 20 | 257 (89.5%) | 133 (85.8%) | 124 (93.9%) |  |
|  | Glucose (mg/dL) | 239.0 (171.0, 309.0) | 228.0 (157.0, 296.5) | 249.0 (195.3, 318.0) | 0.18 |
|  | pH | 7.4 (7.4, 7.5) | 7.4 (7.4, 7.5) | 7.4 (7.4, 7.5) | 0.28 |
|  | pH |  |  |  | 0.37 |
|  | 7.35 - 7.45 | 173 (62.0%) | 92 (60.9%) | 81 (63.3%) |  |
|  | < 7.35 | 42 (15.1%) | 20 (13.2%) | 22 (17.2%) |  |
|  | 7.45 | 64 (22.9%) | 39 (25.8%) | 25 (19.5%) |  |
|  | Anion Gap (mEq/L) | 10.5 (7.1, 14.0) | 10.0 (6.4, 13.4) | 11.4 (7.8, 14.4) | 0.057 |
|  | Anion Gap (mEq/L) |  |  |  | 0.16 |
|  | 7 - 13 | 128 (46.5%) | 68 (45.3%) | 60 (48.0%) |  |
|  | < 7 | 67 (24.4%) | 43 (28.7%) | 24 (19.2%) |  |
|  | 13 | 80 (29.1%) | 39 (26.0%) | 41 (32.8%) |  |
|  | Sodium (mmol/L) | 137.0 (133.0, 142.0) | 137.0 (133.5, 142.0) | 137.0 (133.0, 142.0) | 0.65 |
|  | Potasium (mEq/L) | 3.8 (3.5, 4.2) | 3.8 (3.6, 4.1) | 4.0 (3.5, 4.4) | 0.057 |
|  | Chlorine (mmol/L) | 1.2 (1.1, 1.2) | 1.2 (1.1, 1.2) | 1.2 (1.1, 1.2) | 0.34 |
|  | Calcium (mmol/L) | 1.2 (1.1, 1.2) | 1.2 (1.1, 1.2) | 1.2 (1.1, 1.2) | 0.34 |
| Blood gas findings | SaO2 (%) | 90.0 (83.0, 94.0) | 92.0 (88.0, 95.0) | 85.0 (78.0, 91.3) | **<0.001** |
|  | SaO2 |  |  |  | **0.020** |
|  | = 94 | 80 (27.9%) | 52 (33.5%) | 28 (21.2%) |  |
|  | < 94 | 207 (72.1%) | 103 (66.5%) | 104 (78.8%) |  |
|  | FiO2 (%) | 40.0 (21.0, 80.0) | 38.0 (21.0, 40.0) | 80.0 (32.0, 80.0) | **<0.001** |
|  | FiO2 (%) |  |  |  | 0.23 |
|  | 21 (O2 therapy) | 203 (70.7%) | 105 (67.7%) | 98 (74.2%) |  |
|  | 21 | 84 (29.3%) | 50 (32.3%) | 34 (25.8%) |  |
|  | PaO2:FiO2 ratio | 191.0 (95.1, 298.0) | 238.5 (145.0, 325.3) | 123.0 (77.6, 249.5) | **<0.001** |
|  | PaO2:FiO2 ratio |  |  |  | **<0.001** |
|  | 200 | 135 (47.0%) | 88 (56.8%) | 47 (35.6%) |  |
|  | <= 200 | 152 (53.0%) | 67 (43.2%) | 85 (64.4%) |  |
|  | PaO2 (mmHg) | 73.1 (61.0, 91.0) | 78.0 (68.0, 93.9) | 64.9 (52.2, 80.5) | **<0.001** |
|  | PaO2 |  |  |  | **<0.001** |
|  | = 60 | 223 (77.7%) | 141 (91.0%) | 82 (62.1%) |  |
|  | < 60 | 64 (22.3%) | 14 (9.0%) | 50 (37.9%) |  |
|  | PCO2 (mmHg) | 31.4 (27.9, 35.0) | 32.2 (28.9, 35.0) | 30.2 (26.4, 35.0) | **0.021** |
|  | PCO2 (mmHg) |  |  |  | 0.55 |
|  | < 36 | 222 (77.4%) | 122 (78.7%) | 100 (75.8%) |  |
|  | = 36 | 65 (22.6%) | 33 (21.3%) | 32 (24.2%) |  |
|  | HCO3 (mmol/L) | 20.7 (17.9, 23.0) | 21.1 (19.7, 23.1) | 19.9 (16.0, 22.5) | **0.003** |
|  | HCO3 (mEq/L) |  |  |  | **0.032** |
|  | 21 - 28 | 119 (42.8%) | 75 (50.0%) | 44 (34.4%) |  |
|  | < 21 | 148 (53.2%) | 70 (46.7%) | 78 (60.9%) |  |
|  | 28 | 11 (4.0%) | 5 (3.3%) | 6 (4.7%) |  |
| Treatment | Antibiotics | 278 (96.9%) | 146 (94.2%) | 132 (100.0%) | **0.004** |
|  | Corticosteroids | 208 (72.5%) | 97 (62.6%) | 111 (84.1%) | **<0.001** |
|  | Anticoagulants |  |  |  | **<0.001** |
|  | No | 55 (19.2%) | 41 (26.5%) | 14 (10.6%) |  |
|  | Enoxaparin | 232 (80.8%) | 114 (73.5%) | 118 (89.4%) |  |
|  | Antiparasitics |  |  |  | 0.085 |
|  | No | 231 (80.5%) | 119 (76.8%) | 112 (84.8%) |  |
|  | Ivermectin | 56 (19.5%) | 36 (23.2%) | 20 (15.2%) |  |
|  | Antimalarials |  |  |  | **0.003** |
|  | No | 162 (56.4%) | 100 (64.5%) | 62 (47.0%) |  |
|  | Hydroxychloroquine | 125 (43.6%) | 55 (35.5%) | 70 (53.0%) |  |
|  | Pronation | 115 (44.1%) | 61 (47.3%) | 54 (40.9%) | 0.30 |
| 1Median (IQR); n (%) | | | | | |
| 2Wilcoxon rank sum test; Pearson's Chi-squared test | | | | | |